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of Medicine, Boston, Massachusetts, USA; and 3Biostatistics Program, Ofﬁce of Director, NIDDK, NIH, Bethesda,
Maryland, USAIntroduction: There is broad consensus that high-grade basal proteinuria and failure to achieve remission
of proteinuria are key determinants of adverse renal prognosis in patients with primary membranous
nephropathy. Since current regimens are not ideal due to short- and long-term toxicity and propensity to
relapse after treatment withdrawal, we developed a treatment protocol based on a novel combination of
rituximab and cyclosporine that targets both the B-cell and T-cell limbs of the immune system. Herein, we
report pilot study data on proteinuria and changes in autoantibody levels and renal function that offer a
potentially effective new approach to treatment of severe membranous nephropathy.
Methods: Thirteen high-risk patients deﬁned by sustained high-grade proteinuria (mean 10.8 g/d) received
combination induction therapy with rituximab plus cyclosporine for 6 months, followed by a second cycle
of rituximab and tapering of cyclosporine during an 18-month maintenance phase.
Results: Mean proteinuria decreased by 65% at 3 months and by 80% at 6 months. Combined complete or
partial remission was achieved in 92% of patients by 9 months; 54% achieved complete remission at
12 months. Two patients relapsed during the trial. All patients with autoantibodies to PLA2R achieved
antibody depletion. Renal function stabilized. The regimen was well tolerated.
Discussion: We report these encouraging preliminary results for their potential value to other investigators
needing prospectively collected data to inform the design and power calculations of future randomized
clinical trials. Such trials will be needed to formally compare this novel regimen to current therapies for
membranous nephropathy.
KI Reports (2016) 1, 73–84; http://dx.doi.org/10.1016/j.ekir.2016.05.002
KEYWORDS: cyclosporine; membranous nephropathy; nephrotic syndrome; rituximab
Published by Elsevier Inc. on behalf of International Society of Nephrology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).P rimary membranous nephropathy (MN) is anautoimmune disorder caused by antibodies to
constitutive antigens of glomerular podocytes.1,2 Cell
surface antigen–antibody complexes are capped into
aggregates and shed from podocytes where they bind
to and accumulate along the external lamina of the
glomerular basement membrane. Complement is acti-
vated by the immune complexes and is a key factor
leading to the glomerular proteinuria.
The natural history of MN is variable3–5 and likely
depends on ambient levels of circulating pathogenicspondence: Meryl Waldman, Kidney Diseases Branch, Na-
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International Reports (2016) 1, 73–84autoantibodies. Remissions can occur spontaneously,4,5
presumably by restoration of autoregulation of normal
antibody production, or can be gained by treatment-
induced suppression of pathogenic autoantibodies.
Approximately one-quarter of patients with MN
undergo spontaneous remission, while the vast major-
ity are prone to persistent high-grade proteinuria,
approximately one-half of whom are at risk of pro-
gression to renal failure.6
Given the potential toxicities of traditional immu-
nomodulatory drugs, decisions regarding therapy must
take into account the natural history of the disease and
objective efﬁcacy of the various therapeutic options
balanced against the risks of protracted nephrotic
syndrome (NS) and loss of renal function, as well as
risks of drug toxicities. Current guidelines support
limiting the use of immunosuppressive treatment to73
CLINICAL RESEARCH M Waldman et al.: Rituximab Plus Cyclosporine for MNpatients who are considered at medium and high risk of
progression to end-stage kidney disease (ESKD) based
on clinical observations acquired over time.6–9
Accepted treatment options include combination ther-
apy with glucocorticoids and a cytotoxic alkylating
agent or calcineurin inhibitors (CNIs).9 Cytotoxic-based
regimens are often considered as ﬁrst-line therapy for
patients at high risk of progression,9,10 but potential
short- and long-term adverse effects of cytotoxic drugs
(bone marrow suppression, infertility, as well as
infection and malignancy diathesis with greater cu-
mulative exposure) greatly inﬂuence therapeutic de-
cisions.11,12 CNIs lead to earlier reductions in
proteinuria but are associated with high relapse rates
(occurring in almost 50% within a year of drug with-
drawal);13–16 these considerations usually lead to pro-
longed therapy with its attendant risks, particularly
nephrotoxicity. In the continued search for new
treatments that might offer higher therapeutic indices,
there has been growing enthusiasm for use of the B
cell–depleting agent rituximab for MN based on the
central role in disease pathogenesis of IgG autoanti-
bodies to M-type phospholipase A2 receptor (PLA2R),
17
and other glomerular antigens.18,19 Encouraging results
from case series and uncontrolled pilot trials of ritux-
imab have been reported.20–24 However, small series
reported to date show mostly delayed and partial re-
missions of NS, as well as a propensity to relapse after
single courses of rituximab.
In an effort to overcome these unresolved issues and
limitations of conventional therapies for MN, we
initiated a prospective single-arm pilot study to
investigate whether “induction” treatment with the
combination of rituximab plus a 6-month course of
cyclosporine followed by a “maintenance” course of
rituximab might lead to earlier, more complete and
durable clinical and immunologic remissions of MN
than either agent alone. We hypothesized that cyclo-
sporine and rituximab would act synergistically, as
they have different effects on the immune system
(T and B cells, respectively) and on the podocyte, and
distinct onset of action (early vs. delayed, respectively)
as well as duration of action. We envisioned that such
pilot studies were necessary to acquire data that would
inform the design and power calculations for testing
rituximab-based combination therapies in the future.
We considered that the preliminary results regarding
safety and efﬁcacy of this regimen were informative
and merited early publication.
MATERIALS AND METHODS
Patients aged 18 years and older with biopsy-proven
MN were eligible to participate in this study. Patients
were required to have persistent nephrotic-range74proteinuria (>3.5 g/d proteinuria) after a minimum
observation phase of 6 months and at least 2 months of
treatment with renin–angiotensin system blockade.
Presence of PLA2R autoantibody in serum or in
glomerular deposits was not required for inclusion.
Exclusion criteria included estimated glomerular
ﬁltration rate (eGFR) <40 ml/min per 1.73 m2 (deter-
mined by the 2009 CKD-EPI creatinine equation25),
prior treatment with CNI for $6 months, any previous
treatment with rituximab, pregnancy, nursing
mothers, or subjects not practicing birth control.
Patients with an active infection, diabetes, or a likely
secondary cause of MN were excluded. The NIDDK
Institutional Review Board approved the protocol. All
participants provided informed consent as per the
Declaration of Helsinki for Medical Research Involving
Human Subjects. The study was performed at the NIH
Clinical Center in Bethesda, Maryland. Rituximab was
provided by Genentech through its Investigator
Sponsored Trials program. Genentech did not partici-
pate in study design, data collection, or analysis or
writing of the report.
Run-in Period
Potential participants were managed with standard
supportive therapy for a minimum of 6 months prior to
study enrollment (“observation phase”) in order to
assess for spontaneous recovery. During this phase,
they received a regimen of angiotensin-converting
enzyme inhibitors (ACEis), angiotensin receptor
blockers (ARBs), or both, along with adjunctive anti-
hypertensives if necessary to achieve target systolic
blood pressure of <130 mm Hg, statins for control of
lipids, dietary sodium restriction, and loop diuretics to
control edema. Patients were eligible for enrollment in
the treatment trial after the observation phase if they
had persistent nephrotic-range proteinuria that did not
show evidence of decline from baseline. Earlier initia-
tion of immunosuppression was allowed if the patient
suffered from a signiﬁcant complication of the NS, such
as a thrombotic event.
Immunosuppressive Regimen
Experimental treatment consisted of “induction” with
rituximab plus oral cyclosporine followed by “mainte-
nance” rituximab. Both cyclosporine and rituximab
were initiated on day 1 of the formal trial period.
Cyclosporine (Gengraf) was initiated at a dose of
3 mg/kg/d, given in divided equal doses at 12-hour
intervals. The dose was adjusted according to 12-hour
trough blood concentrations to achieve a concentration
of 125 to 190 mg/l and to avoid toxicity. The ﬁrst cycle
of rituximab was given at a dose of 1000 mg i.v. on day
1 and day 15. After 6 months of therapy during theKidney International Reports (2016) 1, 73–84
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mg/d every 3 weeks to discontinuance during the
maintenance phase. Therefore, the duration of the taper
could vary among patients (i.e., occurring over 9 to
21 weeks) depending on the total dose of cyclosporine
that each individual was taking during the induction
phase. All patients were retreated with a second cycle of
rituximab (same dose and 15-day interval) when
the following criteria were fulﬁlled: a minimum of
6 months lapsed since the ﬁrst dose of rituximab and
CD19þ B-cell count was $5 cells/ml (conﬁrmed on
2 values at least 2 weeks apart). Depending on the pace
of B-cell recovery in each individual, the second cycle of
rituximab could be administered at any point during the
cyclosporine taper. Treatment with the second cycle of
rituximab was independent of the remission status.
To reduce the frequency and severity of rituximab
infusion reactions, patients were premedicated with oral
acetaminophen (1000 mg), oral diphenhydramine hy-
drochloride (50 mg), and 100 mg methylprednisolone i.v.
before each infusion. Prophylactic antibacterial or anti-
viral agents were not routinely initiated, with the
following exception: patients with a history of hepatitis B
exposure (HBV surface antigen–negative/core antibody–
positive, HBV DNA–negative) were treated prophylacti-
cally with lamivudine. Prophylactic anticoagulation was
not initiated.
To avoid confounding the interpretation of renal
outcomes, dose escalations of drugs that block the renin–
angiotensin–aldosterone system were not permitted once
immunosuppressive treatment was initiated, but dose
reductions were permitted if clinically indicated. Addi-
tion of other antihypertensive agents were permitted as
needed to achieve target blood pressure control. Patients
were followed for a minimum of 24 months, the duration
of the trial. Extended follow-up beyond the end of the
trial continues regardless of remission status.
Assessments
Clinical and laboratory parameters were collected at
study entry, at 6 weeks, and then at 3-month intervals
until the end of the formal trial period. Blood pressure,
weights, complications of the NS, and side effects of
therapy were registered at every visit. Laboratory
parameters included complete blood counts, electrolytes,
lipid panels, serum albumin, and serum immunoglobu-
lins. Cyclosporine levels were measured by immuno-
assay. Quantiﬁcation of T, B, and natural killer cells was
performed on whole blood (red blood cell lysis method)
using a BD FACS Canto ﬂow cytometer (Becton, Dick-
inson and Company, Franklin Lakes, New Jersey). Pro-
tein excretion was assessed by 24-hour urine collections
and was considered accurate when 24-hour creatinine
excretion was consistent with baseline values. Spot urineKidney International Reports (2016) 1, 73–84protein–creatinine ratios were also collected. Additional
urinary studies included routine urinalysis and direct
microscopic examination of urine sediment (to assess for
dysmorphic red blood cells, white blood cells, casts, and
fat droplets). An inactive urine sediment was deﬁned
as <3 red blood cells per high-power ﬁeld, <5 white
blood cells per high-power ﬁeld, and absence of casts.
The Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation was used for eGFR. Circulating anti-
PLA2R antibodies were determined using a commercially
available enzyme-linked immunosorbent assay kit
(EUROIMMUN US, Mountain Lakes, NJ) that contained
PLA2R1-coated microplates (described in Supplementary
Methods online). Titer values higher than 20 relative
units (RU)/ml are positive; titers of 14 to 20 RU/ml are
considered borderline positive.
Outcome Measures
The primary outcome was the safety proﬁle of the
regimen including serious adverse events and drug-
related adverse events. A serious adverse event was
deﬁned as any adverse event or reaction that results in
death, is life-threatening, results in hospital admission or
extends the length of an existing hospital stay, results in
persistent or serious disability or incapacity, or, based
on appropriate medical judgment, may jeopardize the
subject’s health and may require medical or surgical
intervention to prevent one of the outcomes outlined
above. Adverse events were graded based on the NCI
Common Terminology Criteria for Adverse Events
version 4.0. Secondary outcomes included the propor-
tion of subjects that achieved a complete or partial
remission at 3, 6, 9, 12, 18, and 24 months, time to
remission, and the proportion of patients with relapse.
Remission status was based on degree of proteinuria
measured with 24-hour urinary collection and conﬁrmed
with a second collection at least 4 weeks apart. If there
was an unexplained discrepancy in repeat proteinuria
values such that it changed remission status at a
particular time point, the higher of the 2 proteinuria
values was selected. Complete remission was deﬁned as
proteinuria #0.3 g per 24 hours, partial remission as
proteinuria #3.5 g per 24 hours and a >50% reduction
from baseline proteinuria, and non-response as <50%
reduction in baseline proteinuria or worsening of pro-
teinuria. Relapse was deﬁned as reappearance of pro-
teinuria to $3.5 g per 24 hours and at least 50% higher
than the lowest post-treatment value in those who pre-
viously achieved a partial or complete remission.
Statistical Methods
This is a pilot study of the safety and feasibility of the
treatment regimen. Thus, all efﬁcacy analyses are
deemed as hypothesis-generating rather than testing an75
Table 1. Demographics and clinical characteristics at study
enrollment
Variable
Number of patients 13
Sex %
Male/Female 56/44
Age at diagnosis (yr) 49.9  13.4
Race or ethnic group (%)
White/Black/Asian/Hispanic 68/13/13/6
Serum creatinine (mg/dl) 1.36  0.14
eGFR CKD-EPI (ml/min/1.73 m2) 62  23
Proteinuria (grams/24 h) 10.8  2.8
Serum albumin (g/dl) 1.8  0.5
Hypertension 67%
Urinary abnormalities (% patients)
Dipstick
Hemoglobin $1þ 81%
Glucosuria $1þ 23%
Sediment (microscopic examination)
Dysmorphic RBCs/acanthocytes 68%
RBC casts 0%
Fatty casts 43%
Fat droplets 100%
Study enrollment deﬁned as initiation of protocol immunosuppressive drugs. Data
presented as mean  SD for continuous variables.
eGFR, estimated glomerular ﬁltration rate; RBC, red blood cell.
CLINICAL RESEARCH M Waldman et al.: Rituximab Plus Cyclosporine for MNa priori hypothesis. Data are summarized using counts
and percentages for categorical variables and means 
SD, medians, and, at times, interquartile ranges and
percentage change in values relative to baseline for
continuous variables. Descriptive statistics include
only values for the ﬁrst 13 patients who have data
complete for the 24-month trial period. If a patient met
criteria for relapse, they were treated “off protocol”
with rituximab and continued to be followed to gather
information about safety. However, efﬁcacy data for
these patients from that point forward were not
included in the analysis. For purposes of calculating
percentages, where applicable (i.e., percentage of re-
missions), all 13 patients are included in the denomi-
nator. For drawing inferences about percentages of
participants experiencing partial or complete remis-
sion, we employ Clopper–Pearson exact binomial con-
ﬁdence intervals. The percent change in urine protein
was modeled without transformation (a longitudinal
model with general mean proﬁle over time and random
intercepts and slopes capturing within-individual
dependence); thus, without relying on normal ap-
proximations, 95% conﬁdence intervals were estimated
using a data resampling method (2.5% and 97.5%
percentile values from 1000 bootstrap replicates).
Where applicable, we employ a statistical signiﬁcance
level of 0.05 for P value. For drawing inferences about
trends over the ﬁrst 24 months, we employ tests and
models based on linear regressions for each individual,
with distinct rates of change during the “induction”
phase (baseline to 6 months) and “maintenance” phase
(from 6 to 24 months) with the exception of percent
change from baseline urine protein; see Supplementary
Methods for greater detail. All summaries, tests, and
models are calculated using statistical software SAS
version 9.3 (SAS Institute Inc., Cary, NC) and R version
3.0 (www.r-project.org).
RESULTS
Fifty-two patients were screened for eligibility to
participate in the experimental treatment phase of the
trial. Sixteen patients met entry criteria and enrolled in
the treatment phase by December 2014. Data on 13
patients who completed 24 months of follow-up were
analyzed in this report. Mean ( SD) follow-up was
41  11 months (range, 24–56). Demographic and
clinical attributes of patients at study enrollment
(initiation of protocol immunosuppression drugs) are
presented in Table 1. Participants were mostly male and
Caucasian and had a mean age of 50 years (range, 21–
72). Mean time from most recent renal biopsy to study
enrollment was 11 months (range, 6–24 months). Four
patients had received treatment with other immuno-
suppressive agents (alkylating agents, mycophenolate76mofetil, steroids) prior to trial enrollment but were
resistant or relapsed. At enrollment, all patients were
severely nephrotic with mean protein excretion of 10.8
g per 24 hours, and had marked hypoalbuminemia with
mean serum albumin of 1.8 mg/dl (range, 0.9–2.7 g/dl).
Six patients were treated with ACEi monotherapy,
3 were treated with ARB, 2 were on a combination of
ACEi and ARB, and 2 patients could not tolerate this
class of drugs due to hypotension. Seven patients
had persistent hypertension despite escalating doses
of ACEi and/or ARB and required addition of other
immunosuppression antihypertensive agents prior to
initiation of study drugs.
Clinical Outcome
Changes in proteinuria for individual patients and
percentages of remissions over time are shown in
Table 2. During the observation phase, proteinuria
increased in all patients from 6 g per 24 hours at time of
renal biopsy to 10.8 g per 24 hours at the start of
protocol immunosuppressive treatment. After initiation
of immunosuppressive study drugs, mean proteinuria
progressively decreased (Table 2 and Figure 1). Overall,
there was a 65% reduction in mean proteinuria from
baseline values within 3 months of starting therapy
(95% conﬁdence interval: 53%–80%) and an 80%
reduction of proteinuria from baseline values within
6 months (95% conﬁdence interval: 68%–92%). Eight
patients (61%) experienced rapid reduction in pro-
teinuria, achieving either partial or complete remissionKidney International Reports (2016) 1, 73–84
Table 2. Changes in urinary protein excretion (g per 24 hours) in individual patients from time of diagnosis to study enrollment to 24 months and
percentages of remission achieved over time
Patient number
Proteinuria (g/24 h)
at time of diagnosis
by renal biopsy
(pre-enrollment)
Proteinuria (g/24 h)
at start of protocol
treatment
(enrollment) 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo 24 mo
1 2.8 10.6 10.9 10.8 14.1 5.7 3.8 1.8 0.80
2 8.3 10.5 1.1 0.20 0.30 0.10 0.20 0.10 0.20
3 9.1 14.1 11.3 3.4 2.1 1.4 1.1 0.80 0.52
4 6.9 13.9 1.1 0.98 0.35 0.21 0.1 0.10 0.10
5 5.3 8.0 1.9 1.27 0.68 0.70 0.67 1.0 3.5 (R)
6 7.0 9.8 7.2 5.9 2.1 7.4 (R) 2.7 1.6 0.69
7 6.1 9.6 1.23 0.22 0.24 0.15 0.18 0.17 0.10
8 10.9 11.2 4.3 1.23 0.26 0.28 0.16 0.16 0.13
9 3.5 15.9 2.9 1.2 1.4 1.34 2.3 2.8 3.0
10 1.8 8.3 4.0 0.44 0.27 0.26 0.21 0.24 0.05
11 6.0 7.3 1.5 0.85 0.85 0.21 0.23 0.15 0.17
12 4.1 13.7 1.1 1.1 0.78 0.59 0.66 0.39 0.37
13 6.2 7.1 0.30 0.20 0.23 0.10 0.10 0.11 0.10
Mean proteinuria,
g/24 h ( SD)
62.6 10.82.8 3.83.7 2.13.1 1.83.8 0.91.6 0.81.1 0.70.9 0.50.9
% PR - - 54% [25,81] 62% [32,86] 54% [25,81] 31% [9,61] 31% [9,61] 38% [14,68] 31% [9,61]
% CR - - 7% [0.2,36] 23% [5,54] 38% [14,68] 54% [25,81] 54% [25,81] 54% [25,81] 54% [25,81]
Total remissions, % - - 61% [32,86] 85% [55,98] 92% [64,100] 85% [55,98] 85% [55,98] 92% [64,100] 85% [55,98]
Proteinuria values based on 24-hour urine collection. Individual patient values shown as well as mean values and percentages of remission at each time point with 95% conﬁdence
intervals. Mean proteinuria increased during the observation phase (period from diagnosis to enrollment) despite initiation and escalation of angiotensin antagonists. Initiation of
protocol immunosuppressive drugs led to decrease in proteinuria at all time points. There were 2 relapses (R) during the trial period. After relapse, patients were treated off protocol with
rituximab. Efﬁcacy data from that point forward were not included in the analysis; their proteinuria values (i.e., mean proteinuria) are included in the table to show response. However,
for purposes of calculating percentages of remissions, all patients are included in the denominator even if relapsed.
CR, complete remission; PR, partial remission.
Figure 1. Box plots of urinary protein excretion from time of diagnosis (biopsy) to study initiation/enrollment (time 0) to 24 months. Proteinuria
increased during the observation phase (from diagnostic biopsy to time 0). After initiation of therapy, there was a rapid reduction in proteinuria
within 3 months. The top and bottom of the box are the estimated 75th and 25th percentiles, respectively. The horizontal lines and “þ” signs
within each box represent the median and mean values, respectively. The vertical dashes denote the largest as well as the smallest data point
that is within 1.5 times the interquartile range (75th to 25th percentile) above the 75th percentile or below the 25th; data points outside of this
range are denoted by open circles. After relapse, patients were treated off protocol. Outcomes and efﬁcacy data of relapsed patients from that
point forward were not included in the analysis.
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CLINICAL RESEARCH M Waldman et al.: Rituximab Plus Cyclosporine for MNby 3 months. By 6 months, 85% of patients had ach-
ieved remission prior to receiving the second cycle of
rituximab. By 12 months, more than half of patients
(54%) achieved complete remission and maintained it
for the duration of the trial period.
Reduction in proteinuria was accompanied by a
progressive increase in mean serum albumin levels
(Table 3). There was a concomitant improvement in
serum IgG levels with most achieving near-normal
levels by 3 months. Complete remission of proteinuria
was associated with an inactive urine sediment and
absence of hematuria and glucosuria. Trends in other
relevant laboratory and clinical parameters are shown
in Table 3.
Nine patients had detectable circulating autoanti-
bodies against PLA2R in pretreatment serum as deter-
mined by enzyme-linked immunosorbent assay, and 1
patient had very low titers by Western blot (Table 4).
One patient had circulating autoantibodies to throm-
bospondin type 1 domain–containing 7A proteins
(THSD7A) as determined by Western blot. Median
(interquartile range) baseline anti-PLA2R titer in sero-
positive patients was 261 RU/ml (143–576). Patients
with baseline anti-PLA2R titers above the median had a
mean baseline proteinuria of 12.6  2.9 g per 24 hours;
those with anti-PLA2R titers at or below the median
had mean baseline proteinuria of 9.8  2.5 g per
24 hours. Mean baseline proteinuria in seronegative
patients was 10.1  3 g per 24 hours. During treatment,
all patients seropositive for anti-PLA2R or anti-THSD7A
became seronegative and achieved remission, regardless
of baseline antibody titer. Time to remission of protein-
uria relative to immunologic remission (lag time) is
shown in Table 4. Three patients had re-emergence of
anti-PLA2R antibodies during the trial period (discussed
in Relapse section later in the text).Table 3. Laboratory and clinical parameters from study enrollment to 24
Study enrollment 3 mo 6 mo
Serum albumin (g/dl)
(Ref. range: 3.5–5.2)
1.80.5 3.20.6 3.50.7
Cholesterol (mg/dl)a 26797 21561 20159
Serum IgG (mg/dl)
(Ref. range: 700–1600)
465146 720109 844133
Serum IgM (mg/dl)
(Ref. range: 40–230)
85.362.1 79.662.4 86.351.4
White blood cells (K/ml) 5.71.7 5.61.8 6.63.4
Hemoglobin (g/dl) 11.41.8 11.51.6 11.11.4
CD19 (cells/ml)b
(Ref. range: 61–321)
184 (139–230) 0 (0–0) 4 (2–57)
Systolic blood pressure (mm Hg)c 125.317 133.514 133.711
Diastolic blood pressure (mm Hg)c 75.69 79.78 77.07
Data are presented as mean  SD with the exception of CD19 counts, which are presented a
aTwelve of thirteen patients on statin at initial evaluation.
bMedian duration of CD19þ B cell depletion (defined as <5 cells/ml) was 172 days (range, 99
rituximab between 6 and 8 months after the first cycle, which was based on the timing of B-c
cNew-onset or worsening hypertension occurred in 54% of patients during treatment, nece
angiotensin–aldosterone system antagonists) to maintain pre-enrollment blood pressure levels
78Changes in Renal Function
During the run-in observation phase (prior to initiation
of protocol immunosuppressive treatment), there was a
modest decline in renal function. Mean serum creati-
nine increased from 0.93  0.06 mg/dl to 1.36  0.14
mg/dl, eGFR decreased from 85 ml/min per 1.73 m2
to 62 ml/min per 1.73 m2, and the slope of decline in
eGFR was L1.89 ml/min per 1.73 m2 per month
(Figure 2 and Supplementary Table 1). Initiation of
renin–angiotensin–aldosterone system antagonism may
partially account for this observation. In 5 patients,
serum creatinine increased by at least 40% during the
run-in phase. The momentum and progressive nature
of renal function decline in these patients appeared
most compatible with immune-mediated kidney
injury as alternative etiologies for acute kidney injury
were ruled out. Initiation of “induction” therapy with
cyclosporine plus rituximab was associated with
further (but non-signiﬁcant) decline in renal function
with the nadir occurring at approximately 6 months.
These changes were temporally associated with
achieving target drug levels of cyclosporine (mean
cyclosporine level: 154 25 mg/l) during the induction
phase. Tapering of cyclosporine during the mainte-
nance phase was associated with improvement in GFR.
By 24 months, there was improvement in renal func-
tion compared to baseline (enrollment) values (Figure 2
and Supplementary Table 1). The overall change in
eGFR from the beginning to the end of the trial (0 to
24 months) was D7.85 ml/min per 1.73 m2.
Relapse
Relapse occurred in 2 patients (patients 5 and 6) during
the 24-month trial period (Table 2). Both had achieved
partial remission prior to relapse. A third patient
(patient 9) relapsed after completion of the trial period.months
9 mo 12 mo 15 mo 18 mo 24 mo
3.60.7 3.80.6 3.80.4 3.80.5 3.90.4
19152 18954 16223 18434 17247
820172 862206 1021183 973150 1009117
6239.0 73.555.7 73.661.8 75.747.5 66.452.8
5.72.0 6.02.0 5.92.4 6.32.6 6.03.1
11.71.2 12.11.3 12.21.4 12.51.4 12.31.1
0 (0–2) 1 (0–5) 3 (0–68) 42 (15–144) 151 (37–277)
123.211 124.215 115.013 114.411 116.910
72.48 69.510 64.56 69.211 67.47
s median (interquartile range).
–254 days) after the first cycle of rituximab. All patients received the second cycle of
ell repletion in each individual patient, as discussed in Methods.
ssitating addition or dose escalation of antihypertensive medications (except renin–
.
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Table 4. Changes in anti-PLA2R autoantibody titers in individual membranous nephropathy protocol patients from study enrollment (baseline) to
24 months
Pt. #
Study enrollment (baseline)
Anti-PLA2R 3 mo 6 mo 9 mo 12 mo 18 mo 24 mo
Time to clinical remission (best achieved)
status (mo)
Achieved partial remission Partial remission Complete remission
1 3260 621 70 55.8 2.8b 2.6b 7.0b 18 NA
3 730.9 46.07 3.6b mb 1.2b 0.86b 0.97b 6 NA
5 Negativea – – – – – 142c 3 NA
6 295.6 5.4b 19b 7.3b 23.9c 1.7b 0.6b 9 NA
9 576.1 0.7b 0.63b 0.65b 1.08b 17.29b 60.66c 3 NA
12 78.5 1.8b 2.4b 2.1b 1.4b 1.8b 1.8b 3 NA
Achieved complete remission
2 162.7 2.4b 1.45b 0.7b 0.8b 1.5b 0.8b 3 6
7 260.5 0.88b 1.01b 0.83b 0.89b 0.83b 1.3b 3 6
10 137.7 1.1b 0.84b 0.63b 0.66b 1.3b 0.87b 6 9
13 142.6 1.4b 1.5b 1.5b 1.5b 1.08b 1.1b 3 3
4 Negative – – – – – – 3 12
8 THSD7Aþ – – – – – – 6 9
11 Negative – – – – – – 3 12
PLA2R antibody titer determined by enzyme-linked immunosorbent assay (ELISA); titer >20 RU/ml is considered seropositive. Subgrouping based on best achieved remission status
(partial vs. complete). Nine patients were PLA2R-seropositive at baseline by ELISA, and 1 patient (
apatient 5) had very low levels as detected by Western blot. During treatment, all
seropositive patients became seronegative and achieved remission. This includes subject 8, who was positive for anti-THSD7A at baseline and had negligible levels at 3 months and
undetectable levels by Western blot for the remaining time points through 24 months.
bTiming of anti-PLA2R seronegative status in previously seropositive patients.
cReturn of detectable anti-PLA2R antibody after previously achieving antibody depletion. These patients experienced clinical relapse and were retreated “off protocol.” Patient 6
experienced remission after retreatment that coincided with anti-PLA2R titer becoming negative again. Time to best achieved clinical remission is shown to allow comparisons between
timing of immunologic and timing of clinical remission (lag time).
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Figure 2. Box plots showing changes in eGFR (CKD-EPI) from the time of diagnosis (biopsy) to study initiation/enrollment (time 0) to 24 months.
Estimates of changes in eGFR over various intervals are based on mixed-effects models. During the observation phase (deﬁned as time from
biopsy to start of study drugs at time 0), there was a decline in renal function; the slope of decline in eGFR was –1.89 ml/min per 1.73 m2 per
month. Initiation of induction therapy was associated with further decline in renal function that improved as cyclosporine was tapered and
discontinued during the maintenance phase (starting at month 7). The change in eGFR during the induction phase was –4.07 ml/min per 1.73 m2
andD11.92 ml/min per 1.73 m2 during the maintenance phase (7–24 months). By 24 months, there was improvement in renal function compared
to enrollment (time 0) values. The top and bottom of the box are the estimated 75th and 25th percentiles. The horizontal lines and “þ” signs
within each box represent the median and mean values, respectively. The vertical dashes denote the largest as well as the smallest data point
that is within 1.5 times the interquartile range (75th to 25th percentile) above the 75th percentile or below the 25th; data points outside of this
range are denoted by open circles. P values compare 0 versus 6 months, 6 months versus 24 months, and 0 versus 24 months.
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PLA2R antibody in these patients (Table 4).
Adverse Events
The experimental immunosuppressive regimen of
cyclosporine and rituximab was well tolerated.
Adverse events were mostly clinically insigniﬁcant
(Table 5). Acute infusion reactions associated with the
ﬁrst dose of rituximab occurred in 6 (37%) patients but
were mild and easily manageable. Five episodes of late-
onset neutropenia (neutrophil count #1  109 cells/l,
at least 4 weeks following rituximab) occurred in 3
patients. There were no episodes of febrile neutropenia.
There were 2 hospitalizations, 1 for diverticulitis and 1
for costochondritis.
DISCUSSION
We present preliminary results of a prospective phase 2
pilot trial using a combination of rituximab plus 6
months of cyclosporine as “induction” therapy followed
by a maintenance phase with rituximab in primary MN.
The concept of the trial is based on the paradigm used
in lupus, vasculitis, and cancer treatment in which
there is a more intensive induction phase, the goal of
which is to achieve remission, followed by a mainte-
nance phase to reduce the risk of relapse. The combi-
nation regimen takes advantage of the different
mechanisms of action of each agent on the immune
system (T and B cells) and on the podocytes, as well as
their variable onset of action, to achieve both immu-
nologic and clinical remission during the inductionTable 5. Adverse events
System Adverse event: no. of patients (%)
Hematologic Neutropenia
Grade 4: 1 (7%)
Grade 3: 3 (23%)
Grade 2: 1 (7%)
Infectious Upper respiratory tract infection: 5 (38%)
Sinusitis: 2 (15%)
Inﬂuenza: 1 (7%)
Rheumatologic Gout: 2 (15%)
Elevated creatine phosphokinase, grade 1: 3 (23%)
Neurologic Dysesthesias (hands and/or feet), grade 1: 3 (23%)
Tremor, grade 1: 1 (7%)
Headache: 3 (23%)
Gastrointestinal Hyperbilirubinemia, grade 1: 3 (23%)
Other liver test abnormalities
(alanine aminotransferase), grade 1: 2 (15%)
Dyspepsia: 2 (15%)
Cardiovascular New-onset hypertension requiring therapy: 2 (15%)
Worsening of hypertension requiring additional therapy: 5 (39%)
Metabolic Hyperkalemia, grade 2: 1 (7%); grade 1: 2 (15%)
Hypomagnesemia, grade 1: 3 (23%)
Hyperglycemia: 1 (7%)
Other Increased hair growth or coarser hair: 4 (30%)
Gingival hyperplasia: 1 (7%)
Grading based on National Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0.
80phase. Cyclosporine inhibits T-cell activation26 and has
well-known effects on the podocyte cytoskeleton that
contribute to the earlier antiproteinuric effects.27 Rit-
uximab suppresses production of pathogenic antibodies
by B cells28 and may also have direct effects on podo-
cyte function and the actin cytoskeleton,29,30 but its
antiproteinuric effects tend to be delayed. The rationale
for retreating with a second cycle of rituximab during
the maintenance phase is to maintain remission and
prevent relapse as the cyclosporine is tapered and
discontinued.
Patients in this pilot study were considered to be at
moderate to high risk of progression to ESKD because
they demonstrated persistent (and increasing) high-
grade proteinuria with or without decline in GFR
during the observation phase. To date, all patients
experienced either a partial or a complete remission with
therapy. Remission rates, particularly the high per-
centage of complete remissions (54% by 12 months), are
encouraging compared with those observed using
currently accepted treatments that include alkylating
agents or CNIs. The combination regimen leads to a
higher proportion of sustained complete remissions than
either rituximab or cyclosporine alone (Table 6). The
signiﬁcance of achieving remission of proteinuria,
especially complete, for long-term renal prognosis is
underscored in an analysis of a large cohort of MN pa-
tients in the Toronto Registry31 followed over 5 years.
No patients who attained complete remission reached
ESKD, and only 9% of patients who achieved partial
remission developed ESKD. In contrast, 29% of patients
who did not achieve a remission progressed to ESKD.
The timing of remissions also deserves to be high-
lighted: 61% of patients achieved either partial or
complete remission by 3 months, leading to shorter
exposure to the metabolic, infectious, and prothrombotic
consequences of the NS compared to treatment with
rituximab monotherapy or with alkylating-based regi-
mens. Thromboembolic complications are among the
most concerning nonrenal consequences of MN accom-
panied by hypoalbuminemia.32,33 Prophylactic warfarin
anticoagulation extending for the duration of the
“at-risk” period is considered for patients with severe
hypoalbuminemia (<2.0 g/dl)34 but may be associated
with bleeding and renal injury35 and necessitates
frequent monitoring. We chose not to provide prophy-
lactic anticoagulation in this trial in light of the afore-
mentioned safety concerns. However, our combination
immunosuppressive regimen was effective in shortening
the critical “at-risk” period, as mean serum albumin
levels increased from less than 2 g/dl at baseline to
greater than 3 g/dl within 3 months.
Our deﬁnition of remission status for this trial
was based on measurement of protein excretion. It isKidney International Reports (2016) 1, 73–84
Table 6. Summary of remission and relapse rates using various immunosuppressive regimens compared to protocol induction/maintenance
regimen for treatment of membranous nephropathy
Treatment regimens
6 mo remissions 12 mo remissions 24 mo remissions
Relapse rates during
trial period (%)% CR % PR % CR % PR % CR % PR
Cyclosporine (6–24 mo) þ steroids13,15 0–7 50–68 7–10 39–40 7–40 32–40 13–48
Tacrolimus (18 mo)14,45 12–23 37–44 26–34 44–48 32 44 44–47
Rituximab20–23,41,46,47 0 29–63 0–18 43–63 20–27 45–60 6–29
Alkylating agent alternating with steroids for 6 mo48–51 10–15 45–50 15–28 35–65 30–40 30–50 10–31
Oral cytoxan for 12 mo þ steroids for 6 mo52 NA NA NA NA 17 77 28
MMF  steroids53–55 5 21 5 31 NA NA 29–57
Adrenocorticotropic hormone (synthetic) for 12 mo56 19 44 38 50 NA NA 21
Protocol regimen Cyclosporine D rituximab 23 62 54 31 54 31 15
Percentage of complete remissions (CR) and partial remissions (PR) achieved in patients with membranous nephropathy at various time points using other immunosuppression regimens
versus the protocol induction/maintenance regimen.
MMF, mycophenolate mofetil; NA, data not available at these time points.
M Waldman et al.: Rituximab Plus Cyclosporine for MN CLINICAL RESEARCHanticipated that future deﬁnitions of remission will
incorporate both clinical and immunologic parameters
(i.e., anti-PLA2R antibody), which may provide a more
accurate assessment of response to therapies and
potential for disease progression than is provided by
proteinuria alone.36–40 The protocol treatment was
effective in inducing immunologic remission. All
patients who were positive for anti-PLA2R or anti-
THSD7A achieved complete antibody depletion dur-
ing the trial. This likely accounts for the high rate of
observed remissions. Disappearance of antibodies has
important implications, as it has been associated with
good long-term outcomes. Bech et al. reported that
almost 60% of patients who are seronegative following
treatment remain in remission for 5 years, whereas
patients who remain seropositive usually do not
maintain remission.36 The efﬁcacy of this regimen on
antibody depletion is similar to that reported using a
cyclophosphamide-containing regimen36,40 but repre-
sents improvement over results reported with ritux-
imab monotherapy in which 25% of patients with
PLA2R-related disease never achieve antibody
depletion.38,41 In accordance with previous studies,
changes in antibody levels preceded the reduction in
proteinuria.38,41,42 Numerous investigators have
described a pattern of steep fall in antibody titers after
initiation of immunosuppression followed by a more
gradual reduction in proteinuria over months to
years.36 This time lag between immunologic and
observed clinical remission was shortened with our
experimental regimen compared with other immuno-
suppressive regimens due to earlier reductions in pro-
teinuria. Anti-PLA2R titers dropped substantially after
immunosuppression initiation such that more than
75% of patients achieved immunologic remission by
3 months and 61% of patients achieved clinical
remission by that time point.
No patients reached a doubling of serum creatinine
or dialysis during the trial period or during extendedKidney International Reports (2016) 1, 73–84follow-up. The protocol treatment was associated with
an early but non-signiﬁcant decline in renal function
during the induction phase that improved as cyclo-
sporine was tapered and discontinued during the
maintenance phase. These observations of reversible
reduction in GFR are in line with the known acute
hemodynamic effects of CNIs. By 24 months, there was
improvement in renal function compared to baseline
(enrollment) values, suggesting that this combination
immunosuppressive regimen may attenuate and
possibly reverse the decline in renal function that
occurred during the observation period. The data on
monotherapy with CNIs and effects on renal survival in
MN are conﬂicting. One randomized trial reported that
cyclosporine slowed the rate of renal function decline
in patients with progressive MN,43 whereas 2 studies
showed faster progression of disease.10,44 The shorter
duration of cyclosporine treatment (6 months) and
lower doses used in our combination immunosuppres-
sive regimen compared with other trials may partly
account for the differences in renal outcomes.
Relapse rates within the 24-month trial period (15%)
and during extended follow-up (23%) are in line with
those reported with alkylating agents, and represent
marked improvement over the high relapse rates seen
after CNI withdrawal. Table 6 compares relapse rates
among different immunosuppression regimens.
This combination regimen was well tolerated, and no
new or unexpected safety signals were observed. The
relatively rapid improvement in hypogammaglobulin-
emia associated with treatment and avoidance of cor-
ticosteroids may have accounted for the low infection
rates in our study compared to those observed with
cytotoxic-based regimens.
Our trial has inherent limitations. It has a single-arm
design and limited sample size. However, the purpose
of this study was to gather both safety and efﬁcacy
data in patients at high risk of progression and in those
with declining renal function. These preliminary data81
CLINICAL RESEARCH M Waldman et al.: Rituximab Plus Cyclosporine for MNare necessary to design and power future controlled
studies. We were rigorous in our attempt to identify
those at highest risk of progression who are more
difﬁcult to treat and tend to suffer more adverse effects
with therapy. Continued enrollment of additional
patients and longer-term follow-up are required to
conﬁrm these results and assess long-term safety of this
combination regimen, relapse-free survival, and impact
on hard renal end points such as ESKD.
The combination of short-term cyclosporine and
rituximab in this induction and maintenance regimen
appears to be effective in achieving both immunologic
and clinical remission in MN patients at high risk of
poor outcomes. This regimen is associated with a high
proportion of complete remissions. We have demon-
strated tolerability and a favorable safety proﬁle even in
patients with declining renal function. Advantages of
this regimen are the relatively short exposure to cyclo-
sporine, less exposure to the complications of the NS
given the more rapid onset of remissions, and avoidance
of the short- and long-term toxicity associated with
steroids and alkylating agents. We believe that these
preliminary ﬁndings support formal comparison of this
regimen with currently accepted immunosuppressive
regimens in a randomized controlled trial.
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